Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 4:1
Drug Approvals
12
NMPA:12
Drug Approvals
Cefodizime Sodium for Injection
- Product Name
- NEWDIZIME
- Approval Number
- 国药准字HJ20160446
- Approval Date
- Nov 4, 2021
NMPA
Cefodizime Sodium for Injection
- Product Name
- NEWDIZIME
- Approval Number
- 国药准字HJ20160445
- Approval Date
- Nov 4, 2021
NMPA
Cefotiam Hydrochloride for Injection
- Product Name
- 注射用盐酸头孢替安
- Approval Number
- H20170184
- Approval Date
- Feb 13, 2019
NMPA
Cefotiam Hydrochloride for Injection
- Product Name
- 注射用盐酸头孢替安
- Approval Number
- H20170187
- Approval Date
- Feb 13, 2019
NMPA
Cefotiam Hydrochloride for Injection
- Product Name
- 注射用盐酸头孢替安
- Approval Number
- H20170186
- Approval Date
- Feb 13, 2019
NMPA
Cefmetazole Sodium for Injection
- Product Name
- 迈力普
- Approval Number
- H20171038
- Approval Date
- Jan 28, 2019
NMPA
Cefmetazole Sodium for Injection
- Product Name
- 迈力普
- Approval Number
- H20171041
- Approval Date
- Jan 28, 2019
NMPA
Cefmetazole Sodium for Injection
- Product Name
- 迈力普
- Approval Number
- H20171042
- Approval Date
- Jan 28, 2019
NMPA
Cefmetazole Sodium for Injection
- Product Name
- 迈力普
- Approval Number
- H20171039
- Approval Date
- Jan 28, 2019
NMPA
Cefmetazole Sodium for Injection
- Product Name
- 迈力普
- Approval Number
- H20171040
- Approval Date
- Jan 28, 2019
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 4
1 (50.0%)Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease
Phase 4
Recruiting
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Daewoong Bio Inc.
- Target Recruit Count
- 630
- Registration Number
- NCT05383183
- Locations
- 🇰🇷
Changwon Fatima Hospital, Changwon, Korea, Republic of
🇰🇷Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷CHA Bundang Medical Center, Seongnam, Korea, Republic of
Pharmacokinetics, Safety, and Tolerability of rhEGF Eye Drops in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: Single dose of rhEGF 50mcg/ml or placeboDrug: Multiple dose of rhEGF 50mcg/ml or placeboDrug: Single dose of rhEGF 100mcg/ml or placeboDrug: Multiple dose of rhEGF 10mcg/ml or placeboDrug: Single dose of rhEGF 10mcg/ml or placeboDrug: Multiple dose of rhEGF 100mcg/ml or placebo
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Daewoong Bio Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05219461
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
News
No news found